Generalized pustular psoriasis following withdrawal of efalizumab.
ML Gaylor, M Duvic - Journal of drugs in dermatology: JDD, 2004 - europepmc.org
ML Gaylor, M Duvic
Journal of drugs in dermatology: JDD, 2004•europepmc.orgEfalizumab is one of the new biologic therapies targeting T-lymphocyte activity for the
treatment of chronic plaque psoriasis. Common adverse effects include headaches,
nonspecific infection, nausea, chills, and fever. Rebound of psoriasis following
discontinuation of the drug has been reported. Relapse events can manifest as recurrent
plaque psoriasis, guttate psoriasis, psoriatic erythroderma, and pustular psoriasis. We report
a second case of withdrawal flare resulting in generalized pustular psoriasis.
treatment of chronic plaque psoriasis. Common adverse effects include headaches,
nonspecific infection, nausea, chills, and fever. Rebound of psoriasis following
discontinuation of the drug has been reported. Relapse events can manifest as recurrent
plaque psoriasis, guttate psoriasis, psoriatic erythroderma, and pustular psoriasis. We report
a second case of withdrawal flare resulting in generalized pustular psoriasis.
Efalizumab is one of the new biologic therapies targeting T-lymphocyte activity for the treatment of chronic plaque psoriasis. Common adverse effects include headaches, nonspecific infection, nausea, chills, and fever. Rebound of psoriasis following discontinuation of the drug has been reported. Relapse events can manifest as recurrent plaque psoriasis, guttate psoriasis, psoriatic erythroderma, and pustular psoriasis. We report a second case of withdrawal flare resulting in generalized pustular psoriasis.
europepmc.org